These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 31821506)
1. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506 [TBL] [Abstract][Full Text] [Related]
2. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF; Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617 [TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459 [TBL] [Abstract][Full Text] [Related]
5. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D; Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Ginzac A; Molnar I; Durando X; Motte Rouge T; Petit T; D'hondt V; Campone M; Bonichon-Lamichhane N; Venat Bouvet L; Levy C; Augereau P; Pistilli B; Arsene O; Jouannaud C; Nguyen S; Cayre A; Tixier L; Mahier Ait Oukhatar C; Nabholtz JM; Penault-Llorca F; Mouret-Reynier MA Breast Cancer Res Treat; 2024 Jun; 205(2):267-279. PubMed ID: 38453781 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. Pizzuti L; Barba M; Giannarelli D; Sergi D; Botti C; Marchetti P; Anzà M; Maugeri-Saccà M; Natoli C; Di Filippo S; Catenaro T; Tomao F; Amodio A; Carpano S; Perracchio L; Mottolese M; Di Lauro L; Sanguineti G; Di Benedetto A; Giordano A; Vici P J Cell Physiol; 2016 Nov; 231(11):2541-7. PubMed ID: 27187274 [TBL] [Abstract][Full Text] [Related]
8. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386 [TBL] [Abstract][Full Text] [Related]
9. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Bonnefoi H; Jacot W; Saghatchian M; Moldovan C; Venat-Bouvet L; Zaman K; Matos E; Petit T; Bodmer A; Quenel-Tueux N; Chakiba C; Vuylsteke P; Jerusalem G; Brain E; Tredan O; Messina CG; Slaets L; Cameron D Ann Oncol; 2015 Feb; 26(2):325-32. PubMed ID: 25467016 [TBL] [Abstract][Full Text] [Related]
12. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS; Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS; Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379 [TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749 [TBL] [Abstract][Full Text] [Related]
17. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V; Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729 [TBL] [Abstract][Full Text] [Related]
18. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098 [TBL] [Abstract][Full Text] [Related]
19. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer. Holmes FA; Hellerstedt BA; Pippen JE; Vukelja SJ; Collea RP; Kocs DM; Blum JL; McIntyre KJ; Barve MA; Brooks BD; Osborne CR; Wang Y; Asmar L; O'Shaughnessy J Cancer Med; 2018 Jun; 7(6):2288-2298. PubMed ID: 29582557 [TBL] [Abstract][Full Text] [Related]
20. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]